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ARTICLE
A network analysis to identify mediators of
germline-driven differences in breast
cancer prognosis
Maria Escala-Garcia et al.#
Identifying the underlying genetic drivers of the heritability of breast cancer prognosis
remains elusive. We adapt a network-based approach to handle underpowered complex
datasets to provide new insights into the potential function of germline variants in breast
cancer prognosis. This network-based analysis studies ~7.3 million variants in 84,457 breast
cancer patients in relation to breast cancer survival and conﬁrms the results on 12,381
independent patients. Aggregating the prognostic effects of genetic variants across multiple
genes, we identify four gene modules associated with survival in estrogen receptor (ER)-
negative and one in ER-positive disease. The modules show biological enrichment for cancer-
related processes such as G-alpha signaling, circadian clock, angiogenesis, and Rho-GTPases
in apoptosis.
https://doi.org/10.1038/s41467-019-14100-6 OPEN
#A full list of authors and their afﬁliations appears at the end of the paper.
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amily-based studies have suggested that breast cancer sur-
vival in ﬁrst-degree relatives has a hereditary component1,2.
Nevertheless, whereas large-scale genome-wide association
studies (GWASs) have made considerable progress in identifying
germline variants linked to breast cancer risk3, the identiﬁcation
of germline variants linked to breast cancer prognosis has proven
more challenging4. An understanding of how and which germline
variants affect breast cancer prognosis could provide novel
insights into the etiology of the metastatic process in breast
cancer, increase knowledge on the underlying heterogeneity of the
disease, and help identify new therapeutic targets or select
patients most likely to beneﬁt from existing therapies.
A major limitation of the studies to date is that the sample sizes
have been insufﬁcient to detect the small effect sizes of germline
variants characteristic for breast cancer risk and survival4–6. Even
though our previous survival GWAS included >95,000 patients4,5,
the limiting factor was the relatively low number of events (breast
cancer-speciﬁc deaths) observed. One way to overcome this
limited power is to use pathway or network-based approaches7,8.
These techniques typically use predeﬁned gene sets, annotated
pathways, or protein–protein interaction (PPI) networks to detect
genetic effects across multiple genes or proteins with similar or
related biological functions6,8–10. Using such methods, a biolo-
gical pathway might emerge as relevant even if none of its indi-
vidual germline variants reached genome-wide signiﬁcance.
Moreover, assigning the variants to genes reduces dimensionality:
considering several pathways as opposed to millions of individual
variants leads to a substantial reduction in the number of tests
performed11. An additional advantage of performing a pathway
analysis is that it naturally suggests which biological processes
mediate the genetic association with survival, making the biolo-
gical interpretation easier7,11–13.
Here we report on a network-based GWAS to identify genetic
determinants of breast cancer prognosis in a dataset with a total
of 84,457 breast cancer patients of European ancestry. In line with
previous studies, we did not ﬁnd many individual genetic variants
with strong effects14–17. However, aggregating the survival esti-
mates of multiple variants across genes and using a network
propagation method, we identiﬁed several biological processes
that may mediate a germline genetic effect on breast cancer
prognosis. These include key processes in cancer biology, such as
regulation of apoptosis, G-alpha signaling, and the circadian clock
mechanism. In our analysis, we show that the identiﬁed polygenic
effects are associated with survival not only in the discovery set
but also in an independent dataset of 12,381 patients. In addition,
we studied the downstream transcriptional changes and their
functional consequences due to the prognostic variants. We
observed similar biological processes in the enrichment of the
downstream and module-level gene analyses suggesting that both
levels are perturbed by the identiﬁed genetic variants.
Results
Single variant and gene analyses detect one independent hit.
We performed an analysis of the association between germline
genetic variants and breast cancer prognosis comprising data for
84,457 female breast cancer patients of European ancestry. To
account for potential subtype-speciﬁc associations, we also per-
formed separate analyses for estrogen receptor (ER)-positive and
ER-negative breast cancer. An overview of all data is given in the
“Methods” section and Supplementary Table 1. As a ﬁrst step in
our analysis, we tested the association of ~7.3 million imputed
genetic variants with breast cancer-speciﬁc survival using a Cox
proportional hazard model (Fig. 1a). Based on a genome-wide
statistical signiﬁcance P value threshold of 5 × 10−8, we identiﬁed
two variants at 8q13, in high linkage disequilibrium (LD) with
each other, associated with survival in ER-positive breast cancer.
The top variant was rs6990375 (chr8:70571531, P= 6.35 x 10−9)
followed by rs13272847 (chr8:70573316, P= 1.07 x 10−8) . We
did not ﬁnd signiﬁcant variants for ER-negative or all breast
cancer cases.
Next, we aggregated the summary statistics of the individual
variants into gene-level P values (~21,800 genes in total) using the
Pascal algorithm12 (Fig. 1b). We computed the gene score based
on the maximum chi-squared signal within a window size of 50-
kb around the gene region (see “Methods”; Fig. 2). Two genes
were associated with survival in ER-positive breast cancer at P <
0.05 after Bonferroni correction: SLCO5A1 (P= 4 × 10−7,
corrected P= 0.01) and SULF1 (P= 7 × 10−7, corrected P=
0.02) (Fig. 2c). These two genes are located in close proximity to
each other around the signiﬁcant variants at 8q13 identiﬁed in the
single variant analysis. Their signiﬁcance is therefore likely driven
by a single causal genetic variant. The top variant rs6990375 is
situated in the 3’ untranslated region of SULF1 where it may
affect the binding of regulatory micro-RNAs. While the
association of this variant with breast cancer survival has not
been identiﬁed previously, it has been reported to be associated
with age of onset of ovarian cancer18. SULF1 has been found to be
involved in cell proliferation, migration, and invasion as well as
drug-induced apoptosis in cancer cell lines19, most likely due to
its regulatory role in ﬁbroblast growth factor20 and Wnt
signaling21. Less is known about the function of SLCO5A1,
although a role in cell proliferation has been suggested22. In line
with the single variant analysis, we found no signiﬁcant genes for
all breast cancer or ER-negative breast cancer (Fig. 2a, b) when
aggregating individual variants into genes.
Network analysis ﬁnds germline-related prognostic modules
(GRPMs). To explore whether weaker signals of association were
hidden in our data, we investigated the hypothesis that the
germline genetic variants associated with breast cancer prognosis
target particular biological processes but within those processes
do not uniquely target one particular gene. Different subgroups of
patients might harbor variants in different genes, which ulti-
mately affect the same biological process. Such polygenic signals,
unless they have very big effects, may remain undetected if only
individual variants or even individual genes are tested. We
therefore applied network propagation23, a technique that maps
gene association scores onto a PPI network and uses the network
topology to detect sub-networks, or modules, of closely inter-
acting, high-scoring proteins (Fig. 1c). In the context of this
paper, we will refer to these modules also as germline-related
prognostic modules (GRPMs).
For the network propagation, we used the HotNet2 method13,
which has been used previously with GWAS data24. We based the
gene scores on the aggregate gene P values computed by the
Pascal method (see “Methods”). The protein interaction network
used by HotNet2 was obtained from iRefIndex25.
When considering all breast cancers, the HotNet2 analysis
identiﬁed no signiﬁcant GRPMs (lowest P= 0.06, based on the
HotNet2 permutation test). In contrast, several GRPMs were
associated with prognosis in the analyses by ER subtype. For ER-
positive patients, the best HotNet2 result (P value <0.01)
comprised 31 GRPMs of ≥7 genes. For ER-negative patients,
the best HotNet2 results (P < 0.01) included 116 GRPMs of ≥4
genes. A list of all signiﬁcant prognostic modules is presented in
Supplementary Data 1.
To help the interpretation of the identiﬁed GRPMs, we
developed an extension to HotNet2 that maps the module genes
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to the speciﬁc genetic variants that are most strongly associated
with prognosis. This was done by performing a Lasso-penalized
Cox regression on the genetic variants assigned to the module
genes. Using those selected variants and their effect sizes, a
polygenic hazard score (PHS) was computed and used to identify
a set of high-conﬁdence GRPMs (Fig. 1d), as well as to perform a
functional characterization of the downstream effects of the
prognostic variants (Fig. 1e).
Prognostic modules point to underlying pathways. We
restricted our scope to a subset of high-conﬁdence GRPMs. This
subset was identiﬁed by testing the association of each module’s
PHS with breast cancer prognosis in an independent set of 12,381
patients (with 1120 events) (Supplementary Table 2) that was not
used previously in the HotNet2 analysis or in the construction of
the PHS score. GRPMs with a signiﬁcant association between
PHS and prognosis (P value <0.05, based on a one-sided Wald
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test) in this independent set were considered high conﬁdence.
Following this procedure, we found four high-conﬁdence GRPMs
for ER-negative breast cancer (Fig. 3a–c) and one high-conﬁdence
GRPM for ER-positive breast cancer (Fig. 3d). Hazard ratios of
the association of the PHSs with breast cancer-speciﬁc survival
ranged from 1.09 to 1.28 (Fig. 3e). In the remainder of this sec-
tion, we will discuss the high-conﬁdence GRPMs. The term PHS
P value will be used to refer to the P value of a GRPM’s PHS
association with survival.
To provide a functional characterization of the ﬁve high-
conﬁdence GRPMs found in the ER-negative and ER-positive
subtypes, we tested each module for enriched biological processes
on two levels. The ﬁrst, which we call the module-level, considers
the direct functions of the GRPM proteins themselves. These
were identiﬁed by an enrichment analysis of the annotated
biological functions of the module proteins and their direct
interactors in a PPI network annotation (see “Methods”). For the
high-conﬁdence GRPMs in ER-negative breast cancer, we
identiﬁed enriched processes related to G-alpha signaling, cell
growth, and angiogenesis; insulin secretion; and circadian clock
(Supplementary Fig. 1a–d). For the ER-positive high-conﬁdence
GRPM, the enriched processes included signaling by Rho
GTPases and apoptosis (Supplementary Fig. 1e).
The module-level enrichment provides a general summary of
the biological functions of the GRPM genes. However, it is based
on functional annotations that have been derived from studies in
many different cell types and biological environments. To study
the speciﬁc downstream effects of the identiﬁed prognostic
variants in breast cancer tumors, we performed enrichment
analyses on the downstream transcriptional changes due to the
prognostic variants affecting the module proteins.
We estimated these downstream transcriptional effects using
genetic variants and RNA expression data of female breast cancer
patients from The Cancer Genome Atlas (TCGA)26. For each of
the ﬁve GRPMs, the downstream analysis was performed on the
subset of TCGA patients matching the ER subtype in which the
GRPM was identiﬁed, 118 patients with ER-negative and 440
with ER-positive tumors. Using the germline genotype data of
these TCGA patients, we computed the PHS for each GRPM
(Supplementary Table 3). Based on these PHSs, we then
computed GRPM downstream transcriptional effect scores, which
reﬂect the correlation between a module’s PHS and the mRNA
expression level of every gene (Fig. 1e; see “Methods”). Using the
obtained downstream transcriptional effect scores, we performed
gene set enrichment analysis (GSEA)27 with gene sets based on
Reactome28 and the MSigDB29 Hallmark gene sets. The
enrichment results for the MSigDB Hallmark gene sets are
shown in Fig. 3, only pathways with a GSEA P value <0.001 and
false discovery rate (FDR) < 0.01 were included in the visualiza-
tion. The full list of enriched processes per high-conﬁdence
GRPM can be found in Supplementary Data 2–6 and Supple-
mentary Fig. 2.
The enriched pathways in the downstream analysis included
biological processes, such as cell cycle, DNA repair, metabolism of
RNA, lipids or proteins, apoptosis, and translation of proteins.
Importantly, we observed overlap of the biological processes
enriched in the downstream analysis and those found for the
module proteins. This observation has two important implica-
tions. First, it provides additional support for the biological role
assigned to the module proteins. In addition to this, in cases
where module proteins may serve several roles, it helps identify
which of those roles is affected by the prognostic variants at a
transcriptional level. The enriched biological processes assigned
to the modules and the related downstream processes are
described below.
ER-negative: G-alpha signaling events: Two high-conﬁdence
GRPMs found for patients with ER-negative tumors (Fig. 3a)
suggested, from the module-level analysis, G-alpha signaling and
Fig. 1 Network analysis pipeline (see “Methods” for details). a Cox models were used to estimate the association between each genetic variant and
breast cancer-speciﬁc survival in 84,457 patients of the Breast Cancer Association Consortium (BCAC) dataset (discovery set). b The P values of the
survival analyses for the genetic variants (blue diamonds) were used to compute gene scores using the Pascal algorithm. These gene scores were based on
the maximum chi-squared signal within a window size of 50-kb around the gene region and accounted for linkage disequilibrium structure (depicted in a
gradient blue scale). c The HotNet2 method was used to identify gene modules based on the −log10 P value of the computed gene scores. d The modules
found by HotNet2 were ﬁltered to obtain a selection of high-conﬁdence germline-related prognostic modules (GRPMs). We constructed a polygenic
hazard score (PHS) summarizing the prognostic effects of a set of selected genetic variants in the module. We then tested the association of this PHS with
survival in both the discovery set (gray) and the independent set (orange). eWe performed a functional characterization of the high-conﬁdence GRPMs by
studying the downstream transcriptional effects. For that, we used genotype and expression data from The Cancer Genome Atlas (TCGA). We computed
the correlation between a GRPM’s polygenic hazard score and the expression of all available genes. Based on these correlation values, a gene set
enrichment analysis assigned biological processes that were enriched among the genes most correlated with the prognostic variants in the GRPM.
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Fig. 2 Manhattan plots of the gene-level associations with breast cancer-speciﬁc survival. Plots show the association in a all breast cancer cases (n=
84,457), b estrogen receptor (ER)-negative (n= 14,529), and c ER-positive (n= 55,701). The −log10 gene P values from the Pascal algorithm is shown on
the y axis and genomic position on the x axis. The top signiﬁcant genes and the most signiﬁcant gene per chromosome (if −log10(P) > 3) are shown in red.
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G-protein activation as biological processes associated with
survival. The ﬁrst GRPM (PHS P= 0.0096) includes ADCY10,
GNA11, PTGIR, and RGS3 (Fig. 3a, right) and the other GRPM
(PHS P= 0.0082) is a larger module of 19 genes: ADRBK2,
CCL16, CNR2, CXCR5, DNAJB4, F2R, GNA15, GNAT1, GRM4,
GUCA1A, GUCA1B, GUCA2B, GUCY2D, HRH4, LTB4R, OPRK1,
OPRM1, RGS9, and RGS9BP (Fig. 3a, left).
On closer inspection of the genetic variants selected for the two
modules’ PHSs, we observed that one genetic variant was shared
by both modules. The other variants in the PHSs, 2 variants in
total for the 4-gene module and 3 variants for the module of 19
genes, were also located in the same genomic region on
chromosome 19p13.3 (Fig. 4a). These variants are upstream of
GNA11 in the former module and GNA15 in the latter. For the
other genes in these two GRPMs, no genetic variants were
selected as part of the modules’ PHSs. This may be due to lack of
statistical power: although the gene scores were high enough to be
included in the module, none of their individual genetic variants
had a strong enough association. The co-location of GNA11 and
GNA15 provides an explanation for why the identiﬁed variants
were selected for both modules. It also suggests that the genetic
associations of these two genes and hence of the two modules are
not independent. Indeed, the patients’ PHSs for both GRPMs are
highly correlated (Fig. 4b), which supports a shared genetic
association. This raises the question of whether the putative
germline genetic effect on survival is mediated through both
genes or only one of the two. In the downstream analyses of both
modules, changes of GNA15 expression were identiﬁed as one of
the strongest downstream transcriptional effects, whereas this is
not the case for GNA11. Conversely, in an independent gene
expression dataset using KMplotter (http://kmplot.com/analysis),
we found that expression of GNA11 is signiﬁcantly associated
with recurrence-free survival in ER-negative breast cancer
(Supplementary Fig. 3), while a similar effect was not seen for
GNA15. These preliminary observations leave open the hypoth-
esis of a role for both genes. A deﬁnitive answer will require more
functional analyses.
In the module-level analysis, the GRPM formed by four genes
also showed enrichment for insulin secretion. It has been shown
that there is a close relationship between G-proteins and their
coupled receptors (GPCR), insulin, and the insulin-like growth
factor I receptor. Altered versions of this crosstalk could play a
role in cancer cells30,31. For example, it has been proposed that, in
cancer cells, insulin can increase the activity of GPCRs in cancer
tissues via the mTOR (mammalian target of rapamycin)
pathway31, which was also one of the enriched processes in the
downstream analysis. The highest scoring gene in the module,
GNA11, codes for the alpha subunit of the G11 protein, which has
been linked to insulin secretion and signaling32,33.
For the 19-gene GRPM, we also identiﬁed thrombin signaling
and platelet aggregation as two of the main module-level enriched
pathways. Thrombin is a type of the above-mentioned GPCRs
with the capacity to upregulate genes able to induce, or contribute
to oncogenesis and angiogenesis, and is known to be able to
stimulate the adhesion of tumor cells to platelets34. In the
downstream analysis, we identiﬁed processes such as GPCR
ligand binding and hemostasis, which contributes to the
thrombosis process and therefore is also linked to GPCRs35
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(Supplementary Fig. 2a and Supplementary Data 2). It has been
reported that hemostatic elements such as platelets, coagulation,
and the ﬁbrinolytic system might play an important role in breast
cancer progression and metastasis36.
ER-negative: circadian clock: Another module identiﬁed by our
network analysis consists of four genes with a strong link to the
circadian clock mechanism: PER1, PER3, TIMELESS, and TIPIN
(PHS P= 0.030; Fig. 3b). Having an important role in the
regulation of the cell cycle37, the circadian clock is believed to be
important in the development of cancer. Disrupted sleep patterns
and associated changes to the body’s circadian rhythm have long
been implicated in the risk of developing several cancers,
including breast cancer37–39. Although long-term night-shift
work has not consistently been found to be associated with breast
cancer40, one study reported an increased risk of ER-negative
breast cancer41. More recently, genetic variants in circadian clock
genes have been reported to be associated with breast cancer
risk42,43. In addition to risk, the circadian clock has also been
suggested to be involved in breast cancer progression and
prognosis44,45.
More speciﬁcally, the circadian clock genes in this module have
also individually been implicated in the biology of cancer in
general and breast cancer in particular. The period genes PER1
and PER3 have been found to suppress cancer cell growth46,47
and have also been observed to be deregulated in breast cancer48.
TIMELESS and its interactor TIPIN are believed to be central
players in the connection between the circadian clock and the cell
cycle and apoptosis49,50. The importance of these genes in the
regulation of the cell cycle was supported by the downstream
analysis, which pointed out that cell cycle-related processes are
strongly enriched among the downstream transcriptional
changes.
ER-negative: regulators of cell growth and angiogenesis: The last
high-conﬁdence GRPM identiﬁed for ER-negative breast cancer
contains proteins that have been linked to regulation of cell
growth or angiogenesis: CHCHD4, PDE9A, SLC36A1, and
PHYHIPL (PHS P= 0.027; Fig. 3c). Knock down of CHCHD4
has been found to reduce tumor growth and angiogenesis
in vivo51. In addition, CHCHD4 has been observed to mediate the
mitochondrial translocation of p5352 through which it may
trigger apoptosis via the p53 mitochondrial pathway53. PDE9A is
a regulator of cGMP signaling, a pathway that is increasingly
being recognized as an important player in breast cancer
biology54. Inhibition of PDE9A has been found to trigger
apoptosis in both ER-positive and ER-negative breast cancer cell
lines55. SLC36A1, also known as PAT1, has been linked to tumor
cell growth through its involvement in the activation of
mTORC1. PHYHIPL (or PAHX-AP1) has mostly been described
in the context of neuronal cells, but no role in cancer has been
described.
ER-positive: Rho GTPases in apoptosis and cell growth: For ER-
positive tumors, we identiﬁed one high-conﬁdence module (PHS
P= 0.020; Fig. 3d). The module was predicted to be involved in
Rho GTPases effectors, which typically function as binary
switches controlling a variety of biological processes. Because of
their ability to control cell motility, they have been hypothesized
to play a role in progression and metastatic dissemination of
cancer cells56. This GRPM contains seven genes: ARHGAP10,
CCNT2, CDR2, HEXIM1, NEUROD2, PKN1, and ZFAND6.
ARHGAP10 (rho GTPase Activating Protein 10) was previously
reported as the most signiﬁcant locus (P= 2.3 × 10−7) in a
GWAS of breast cancer survival14. The top scoring gene in the
module, PKN1 (protein-kinase-C-related kinase), controls pro-
cesses such as regulation of the intermediate ﬁlaments of the actin
cytoskeleton, tumor cell invasion, and cell migration57. It is
activated by the Rho family of small G-proteins and might
mediate the Rho-dependent signaling pathway58, which was one
of the main enriched pathways in the module-level analysis.
PKN1 has also been described as an important player in other
cancers: in androgen-associated prostate cancer by controlling
migration and metastasis57 or in melanomas by inhibiting Wnt/
β-catenin signaling and apoptosis58.
From the module-level analysis, another enriched main process
was the pathway linked to PTEN (phosphatase and tensin
homolog deleted on chromosome 10) regulation, which is a well-
characterized tumor suppressor59. PTEN is directly involved in
the metabolism of phospholipids and lipoproteins60, adaptive
immune system, and B cell receptor associated events,61 which
were all hits in the downstream analysis. One of the six genes in
the module, HEXIM1 (hexamethylene bisacetamide-inducible
protein 1), is a positive regulator of p53 and has been identiﬁed as
a potential novel therapeutic target modulating cell death in
breast cancer cells62. In the downstream analysis of this module,
we also identiﬁed processes present in the module-level analysis
that highlighted key tumorigenic biological processes (Supple-
mentary Data 6), for instance, pathways related to p53 activity,
Wnt signaling, regulation of mRNA stability by proteins that bind
AU-rich elements, or apoptotic execution phase.
GNA15
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Fig. 4 Genomic region 19p13.3 with the two genes GNA11 and GNA15. The
two G-alpha signaling high-conﬁdence germline-related prognostic
modules (GRPMs) identiﬁed in the estrogen receptor (ER)-negative
subtype have a shared genetic signal in the same genomic region. a Top:
−log10(P) for the association with survival (y axis) of all variants in the
region 19p13.3 (y axis). Bottom: regression coefﬁcients from the survival
model for the genetic variants in the module’s polygenic hazard scores
(PHSs). b Scatter plot comparing the two modules’ PHSs in the iCOGS
independent validation set. PHS of the GNA11 GRPM on the x axis and PHS
of the GNA15 GRPM on the y axis.
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Discussion
There is evidence that breast cancer prognosis has a heritable
component2,63,64. Exploring the possible link between germline
genetic variants and breast cancer survival may help to develop
better criteria for breast cancer stratiﬁcation, which might have
implications for breast cancer prognostication and treatment65.
However, identifying germline genetic variants associated with
breast cancer prognosis has been challenging so far, mainly
because the current sample sizes have been insufﬁcient to detect
small effect signals.
In this work, we started with a survival analysis based on
individual germline variants similar to the previous GWAS we
have undertaken4. While in the previous analyses no variants
reached genome-wide signiﬁcance, here we identiﬁed two
genome-wide signiﬁcant variants for ER-positive tumors
(rs6990375: P < 6.35 × 10−9 and rs13272847: P= 1.07 × 10−8)
located in 8q13. More complete follow-up and more conservative
variant ﬁltering per dataset (only including variants with impu-
tation r2 > 0.8) may have enabled identiﬁcation of these variants
that remained below genome-wide signiﬁcance in our previous
study (P= 3.02 × 10−5 and P= 1.73 × 10−5, respectively). In the
gene-level analysis, we found two signiﬁcant genes (SLCO5A1 and
SULF1, P < 0.05 after Bonferroni correction) associated with
breast cancer survival. It is likely that both associations were
driven by the identiﬁed leading variant rs6990375.
To address the lack of power in the individual germline variant
and gene-level analyses, we developed a network analysis method
that revealed ﬁve high-conﬁdence GRPMs associated with breast
cancer prognosis. We identiﬁed four modules speciﬁc for ER-
negative breast cancer and one for ER-positive breast cancer. The
GRPMs comprise crucial processes such as cell cycle and pro-
gression, regulation of apoptosis, signaling by mTOR, immune
system, G-alpha signaling, and the circadian clock. These pro-
cesses are already known to play a role in cancer biology in
general and breast cancer prognosis speciﬁcally. However, our
results highlight the possible regulatory impact of germline var-
iants on these processes, which traditionally has received little
attention in cancer survival studies. The broad range of genes and
functions seems to indicate, as already hypothesized, that breast
cancer survival is a complex phenotype inﬂuenced by many
factors and biological mechanisms.
The analysis by ER status subtypes identiﬁed signiﬁcant asso-
ciations that were not present when analyzing all patients toge-
ther. This is in line with the breast cancer risk analyses
undertaken in this same dataset, where the ER subtype analyses
also identiﬁed new associations3. In addition, the main classiﬁ-
cation of breast cancer tumors used for prognosis and treatment
selection is based on immunohistochemical markers such as ER,
progesterone receptor, and HER2 status, reﬂecting the fact that
each group has a different etiology and prognosis. This
assumption is further supported by a comparison of the gene
association scores between the ER status subtypes. The gene
scores for ER-positive and ER-negative breast cancer are uncor-
related (Supplementary Fig. 4c) (Pearson correlation=−0.002),
while the gene scores for all breast cancer cases seem to resemble
the ER-positive subtype more (Supplementary Fig. 4a; Pearson
correlation= 0.366) than the ER-negative subtype (Supplemen-
tary Fig. 4b; Pearson correlation= 0.197). In addition, we found
that the distribution of PHSs across patients was similar for ER-
positive and ER-negative breast cancer patients (Supplementary
Fig. 5), but importantly, each PHS was associated with prognosis
only for the subtype in which it was found (Supplementary
Table 4). These differential associations across subtypes suggest
that prognosis is inherited differently for these two different
disease classes.
The network-based approach and the stratiﬁcation of patients
by ER status enabled a reﬁned interpretation of the GWAS
results5,66, but the ﬁndings are still limited due to the number of
deaths observed, limited follow-up, missing treatment informa-
tion, and possibly remaining heterogeneity of tumor subtype
within the ER classes. Increased sensitivity and speciﬁcity of the
results could be achieved by including additional patients and by
adjusting for more ﬁne-grained tumor characteristics and the
treatment received. Moreover, the network propagation results
are dependent on the completeness of the PPI network used. As a
notable consequence of this, we did not identify modules con-
taining the two gene-level signiﬁcant hits SLCO5A1 and SULF1,
due to the fact that the PPI network did not contain the proteins
they code for.
The modules that are identiﬁed also depend on the speciﬁcity
of the PPI network to the disease-relevant tissue. Many proteins
have tissue-speciﬁc expression patterns and functions; hence not
all interactions in a generic PPI network are found in all tissues.
The use of a tissue-speciﬁc PPI network may prevent discovery of
false positive modules. One single most relevant tissue for our
analysis is not easily identiﬁed though. Unlike the somatic
mutations found in tumor cells, the germline variants we studied
are present in every cell of the body. Their effect on survival may
therefore be mediated by cell types or tissues other than the
cancerous breast tissue. These include the various cell types
present in the tumor microenvironment or distant tissues that
form the pre-metastatic niche. Furthermore, a PPI network spe-
ciﬁc for healthy breast tissue may not accurately describe the
interactions active in transformed cancer cells. In our analysis, we
used a generic PPI network. To prevent false positive modules, we
complemented the network propagation with an extra ﬁltering
step in which we select high-conﬁdence modules based on their
association with survival.
Using curated protein interaction networks such as iRefIndex
in propagation analyses may cause a subtle type of ascertainment
bias: more interactions tend to be known for better studied
proteins, which proteins involved in tumor initiation and pro-
gression often are. As a result, gene scores may correlate posi-
tively with the number of interactions in the protein interaction
network. This is the case, for example, when gene scores are based
on somatic mutation frequencies in cancer. HotNet2 only con-
trols for this partially, whereas a recent extension to the HotNet2
method provides a more rigorous solution67. We tested whether
our analysis was vulnerable to this ascertainment bias by calcu-
lating the correlation between the gene scores computed by Pascal
and the number of interactions recorded by iRefIndex. For all,
ER-positive, and ER-negative breast cancer, these correlations
were close to zero (Pearson r2=−0.012, r2=−0.006, and r2=
0.003, respectively) showing no evidence of ascertainment bias
due to proteins’ numbers of recorded interactions.
In summary, our network propagation analysis shows a
germline genetic link to breast cancer survival and proposes a
mechanism by which multiple loci with small individual effects
might inﬂuence breast cancer-speciﬁc prognosis. Experimental
follow-up of the high-conﬁdence GRPMs identiﬁed is required to
better understand the role of these modules. While we focused on
the subset of high-conﬁdence modules, the other modules may
also yield new insights if assessed in the context of larger inde-
pendent datasets. Together the results presented here may feed
future hypotheses about the contribution of germline variation to
breast cancer survival.
Methods
Breast cancer patient data. We used data from 12 GWASs that together account
for 84,457 invasive breast cancer patients with 5413 breast cancer-speciﬁc deaths
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within 10 years (events). These included 55,701 patients with ER-positive breast
cancer (2854 events) and 14,529 patients with ER-negative breast cancer (1724
events), while the ER status was unknown for the remaining 14,227 patients. All
patients were females of European ancestry. A summary of the studies with the
numbers of patients and events by study is given in Supplementary Table 1. The
GWAS sample sets were genotyped using a variety of genotyping arrays, targeting
between 200,000 and 900,000 variants across the genome, and subsequently
imputed using a common reference (details given below). The majority of patients
came from the Breast Cancer Association Consortium (BCAC), which itself
comprised 69 studies from across the world that underwent a uniform data har-
monization and quality control (data freeze 10). Genotyping in BCAC was per-
formed in two rounds using two different genotyping platforms: iCOGS and
OncoArray. In subsequent analyses, we treated these two platforms as different
studies. The OncoArray dataset is the largest in BCAC, with higher-quality
imputed genotypes compared to the iCOGS data. As an independent dataset, we
separated out the entire SEARCH study, comprising 12,381 patients and 1120
events, from the BCAC data. Patients in the SEARCH study were recruited in the
United Kingdom. Their genotypes were obtained using either iCOGS or
OncoArray (Supplementary Table 2). Participants of all the studies provided
written informed consent and studies were approved by local medical ethical
committees.
Genotype data and sample quality control. Quality checks were performed by
the original studies3,5,68. Genotypes for all 12 datasets were imputed using a
reference panel from the 1000 Genomes Project69 March 2012 release. Imputation
was performed by a two-stage procedure3 using SHAPEIT70 for pre-phasing and
IMPUTE271 for genotype imputation. The genome-wide analyses were performed
on ~7.3 million variants that had a minor allele frequency (MAF) > 0.05 and were
imputed with imputation quality r2 > 0.8 in at least one of the studies.
GWAS survival analysis and summary statistics. The survival analysis was
performed for all invasive breast cancer cases combined and for each of the ER
status subtypes (ER-positive and ER-negative) individually. A Cox proportional
hazards model was ﬁtted to assess the association of the genotype with breast
cancer-speciﬁc survival. Time to event was calculated from the date of diagnosis.
Yet, because patients were recruited at different times before or after diagnosis,
time at risk was calculated from the recruitment date (left truncation) in order to
avoid possible bias produced by prevalent cases. Follow-up was right censored on
the date of death if the patient died from a cause other than breast cancer, the last
date the patient was known to be alive if death did not occur, or at 10 years after
diagnosis, whatever came ﬁrst. To control for cryptic population substructure, we
adjusted for principal components3 (for the number of principal components per
study, see Supplementary Table 1). Since BCAC-OncoArray and BCAC-iCOGS
comprised data from large international cohort studies, the Cox models for these
datasets were stratiﬁed by country. Separate survival analyses were performed for
each of the 12 main studies, after which overall results per variant were obtained by
combining the results of all studies with imputation quality r2 > 0.8 for that variant
using a ﬁxed-effects meta-analysis. P values were computed using a two-sided
Wald test.
From variant P values to gene scores. We used the GWAS summary statistics
from the survival analysis as input for computing gene scores. To obtain gene
scores, we used the Pascal algorithm12, which combines variant P values while
taking into account dependence due to LD structure. The Pascal method imple-
ments two gene-level statistics, corresponding to the strongest single association
per gene (maximum of chi-squared statistics) or the average of all associations
across the gene (sum of chi-squared statistics). After computing both statistics, we
tested which one had more power. To this end, we represented the set of P values
into a quantile–quantile (QQ)-plot (Supplementary Fig. 6). For all breast cancer
cases and for both ER status groups, the QQ-plots suggested that the maximum
statistic has more power than the sum statistic. Therefore, of the two gene statistics
we chose the maximum of chi-squared statistics for the gene-level statistic.
For the LD reference population used in the gene computation, we created an
extended version that included more variants than the default library provided with
Pascal. This reference population was based on 503 European genomes from the
1000 Genomes Project (1KG)69. For the remaining parameters, we used the default
settings. First, only variants with an imputation quality r2 > 0.8 and MAF > 5% in
the patient data were considered. Second, the mapping of the variants to genes was
based on the Pascal’s default 50-kb window size from the start and end of the gene.
Finally, when computing gene scores, HLA genes were excluded. After the gene
score computation, we obtained 21,815 gene scores for all invasive breast cancer,
21,789 for ER-positive and 21,797 for ER-negative. The slightly different numbers
of gene scores between groups are due to the distinct selection of variants, which
may have different allele frequencies across groups. The gene scores used in the
HotNet2 analysis were obtained by taking the −log10 of the gene P values
computed with Pascal.
Network propagation with HotNet2. We performed a network propagation
analysis using the HotNet2 algorithm10 and the PPI network iRefIndex25 applied to
the −log10 gene scores obtained from the previous step. For edge removal on the
created modules, HotNet2 automatically selects four different values which
determine four different edge removal thresholds. The signiﬁcance test is a two-
stage statistical test based on the number and size of the identiﬁed modules
compared to those found using a permutation test. We used 500 permutations and
a minimum network size of 2 for statistical testing. Further details are provided in
the original HotNet publication72,73.
Construction of PHSs. To summarize the total prognostic effect of the hereditary
variants within the signiﬁcant GRPMs, we constructed PHSs, using a two-step
approach. First, we selected the set of variants that best represented the genetic
association of breast cancer survival with each GRPM. This variant selection was
performed on the BCAC-OncoArray data, since this was the largest study and had
the highest imputation quality. We performed the selection using the glmnet R
package74, ﬁtting a Lasso (alpha= 1) model with tenfold cross-validation to tune
the sparsity penalty and the same selection of input variants as used for the
computation of the Pascal gene scores, that is, picking those variants with MAF >
5% and within a 50-kb window around the start and end of the gene. With the set
of germline variants selected using the Lasso procedure (Supplementary Table 3),
we ﬁtted a Cox model to estimate unpenalized coefﬁcients and extracted their effect
size estimates to compute a PHS per GRPM, which characterized the whole set of
variants for the speciﬁc module in a unique score. For a set of selected variants {1,
…,n}, the PHS is deﬁned as in (1):
PHS ¼
Xn
i¼1
Xiβi ð1Þ
where Xi is the genotype for the ith variant and βi its associated coefﬁcient.
Identiﬁcation of high-conﬁdence GRPMs. We obtained a selection of high-
conﬁdence GRPMs from among all modules identiﬁed using HotNet2 by testing
the association of each module’s PHS in two datasets. The ﬁrst dataset was the
BCAC-OncoArray data minus the SEARCH data component of BCAC, i.e., the
same data on which the PHS was derived, which was also a subset of the data used
in the HotNet2 analysis. The second dataset consisted of the SEARCH study, which
was held out of the BCAC data to serve as a truly independent set. Only GRPMs
that had a PHS signiﬁcantly associated (P < 0.05) with breast cancer-speciﬁc sur-
vival in both the BCAC-OncoArray and the independent SEARCH data were
considered high-conﬁdence GRPMs and kept for further analysis. To test the
association of a PHS with prognosis, we ﬁtted a Cox model to the PHS, adjusted for
the ﬁrst two genetic principal components and stratiﬁed by country. We then
calculated a one-sided P value for the association of the PHS covariate with sur-
vival, taking advantage of the fact that the direction of association of the PHS is
predeﬁned, i.e., lower PHS means better survival. For the BCAC OncoArray data,
the P value was corrected for multiple testing using Bonferroni correction based on
the number of modules tested. The independent SEARCH data comprised two
subsets using either OncoArray or iCOGS data. We analyzed these two subsets
separately and then combined the results of both groups using a ﬁxed-effect meta-
analysis.
Functional enrichment analysis of GRPM members. Using the Cytoscape ver-
sion 3.4.0 software75, we extended the GRPMs by adding the ﬁrst direct neigh-
boring genes in the Mentha76 human PPI network. With the extension of the
GRPMs, we obtained bigger modules placed in a functional context. We then used
the Cytoscape app ClueGO77. ClueGO uses kappa statistics to group the elements
of the network and creates organized pathway categories based on the integrated
pathway annotation. We based the analysis on human Reactome28 pathways, a
Kappa Score Threshold of 0.4, and Bonferroni correction for the computed
enrichment P values. For the visualization, we selected the fusion feature that
groups pathways according to overlapping genes to facilitate interpretation of the
results. We selected pathways with a P value <0.05.
Downstream functional enrichment. In order to add biological and functional
interpretation to the GRPMs, we looked for associations between the modules’
PHSs and the expression patterns of potential downstream genes (Fig. 1e). From
TCGA26 library, we extracted matched RNA-seq and genotype data of female
breast cancer patients of European ancestry. This resulted in 118 patients with ER-
negative breast cancer and 440 patients with ER-positive breast cancer. For each
GRPM, we computed the previously obtained PHS for the subset of TCGA patients
with a tumor matching the subtype for which the GRPM was found. Next, we
aimed to quantify the downstream transcriptional effect of the GRPM on the
expression of every individual gene. To do so, we computed the Pearson correlation
between the GRPM’s PHS and the RNA expression of each gene. Finally, we
performed GSEA27 to test for enrichment of biological pathways among the highly
correlating genes. We used an annotation set of Reactome pathways28 and
MSigDB29 Hallmark gene sets to perform the pre-ranked GSEA. We visualized the
Reactome results with the EnrichmentMap78 Cytoscape app. Only biological
processes with P value <0.001 and FDR < 0.05 were considered as signiﬁcantly
enriched.
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Ethical Approval. The study was performed in accordance with the Declaration of
Helsinki. All individual studies, from which data was used, were approved by the
appropriate medical ethical committees and/or institutional review boards. All
study participants provided informed consent.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All 10-year breast cancer-speciﬁc survival summary estimates are available via the BCAC
website (http://bcac.ccge.medschl.cam.ac.uk/bcacdata/). Individual patient data will not
be made publicly available without request due to restraints imposed by the ethics
committees of individual studies. Formal request can be made via the Data Access
Coordination Committee (DACC) of BCAC (http://bcac.ccge.medschl.cam.ac.uk/). A
subset of the data that supports the ﬁndings of this analysis is available at https://portal.
gdc.cancer.gov/ (accession number phs000178).
Received: 31 January 2019; Accepted: 17 December 2019;
References
1. Lindström, L. S. et al. Prognostic information of a previously diagnosed sister
is an independent prognosticator for a newly diagnosed sister with breast
cancer. Ann. Oncol. 25, 1966–1972 (2014).
2. Verkooijen, H. M. et al. Breast cancer prognosis is inherited independently of
patient, tumor and treatment characteristics. Int. J. Cancer 130, 2103–2110
(2012).
3. Michailidou, K. et al. Association analysis identiﬁes 65 new breast cancer risk
loci. Nature 551, 92–94 (2017).
4. Escala-Garcia, M. et al. Genome-wide association study of germline variants
and breast cancer-speciﬁc mortality. Br. J. Cancer 120, 647–657 (2019).
5. Guo, Q. et al. Identiﬁcation of novel genetic markers of breast cancer survival.
JNCI J. Natl Cancer Inst. 107, djv081–djv081 (2015).
6. Wang, K., Li, M. & Hakonarson, H. Analysing biological pathways in genome-
wide association studies. Nat. Rev. Genet. 11, 843–854 (2010).
7. Menashe, I. et al. Pathway analysis of breast cancer genome-wide association
study highlights three pathways and one canonical signaling cascade. Cancer
Res. 70, 4453–4459 (2010).
8. Baranzini, S. E. et al. Pathway and network-based analysis of genome-wide
association studies in multiple sclerosis. Hum. Mol. Genet. 18, 2078–2090
(2009).
9. Luo, L. et al. Genome-wide gene and pathway analysis. Eur. J. Hum. Genet. 18,
1045–1053 (2010).
10. Leiserson, M. D. M. et al. Pan-cancer network analysis identiﬁes combinations
of rare somatic mutations across pathways and protein complexes. Nat. Genet.
47, 106–114 (2015).
11. Petersen, A., Alvarez, C., DeClaire, S. & Tintle, N. L. Assessing methods for
assigning SNPs to genes in gene-based tests of association using common
variants. PLoS ONE 8, e62161 (2013).
12. Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z. & Bergmann, S. Fast and
rigorous computation of gene and pathway scores from SNP-based summary
statistics. PLOS Comput. Biol. 12, e1004714 (2016).
13. Marbach, D. et al. Tissue-speciﬁc regulatory circuits reveal variable modular
perturbations across complex diseases. Nat. Methods 13, 366–370 (2016).
14. Azzato, E. M. et al. A genome-wide association study of prognosis in breast
cancer. Cancer Epidemiol. Biomark. Prev. 19, 1140–1143 (2010).
15. Kiyotani, K. et al. A genome-wide association study identiﬁes locus at 10q22
associated with clinical outcomes of adjuvant tamoxifen therapy for breast
cancer patients in Japanese. Hum. Mol. Genet. 21, 1665–1672 (2012).
16. Shu, X. O. et al. Novel genetic markers of breast cancer survival identiﬁed by a
genome-wide association study. Cancer Res. 72, 1182–1189 (2012).
17. Raﬁq, S. et al. Identiﬁcation of inherited genetic variations inﬂuencing
prognosis in early-onset breast cancer. Cancer Res. 73, 1883–1891 (2013).
18. Han, C. H. et al. Polymorphisms in the SULF1 gene are associated with early
age of onset and survival of ovarian cancer. J. Exp. Clin. Cancer Res. 30, 5
(2011).
19. Lai, J.-P., Sandhu, D. S., Shire, A. M. & Roberts, L. R. The tumor suppressor
function of human sulfatase 1 (SULF1) in carcinogenesis. J. Gastrointest.
Cancer 39, 149–158 (2008).
20. Emerson, C. P. et al. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits
ﬁbroblast growth factor signaling in mesoderm induction and angiogenesis.
Proc. Natl Acad. Sci. 101, 4833–4838 (2004).
21. Ai, X. et al. QSulf1 remodels the 6-O sulfation states of cell surface heparan
sulfate proteoglycans to promote Wnt signaling. J. Cell Biol. 162, 341–351
(2003).
22. Sebastian, K. et al. Characterization of SLCO5A1/OATP5A1, a solute carrier
transport protein with non-classical function. PLoS ONE 8, e83257 (2013).
23. Cowen, L., Ideker, T., Raphael, B. J. & Sharan, R. Network propagation: a
universal ampliﬁer of genetic associations. Nat. Rev. Genet. 18, 551–562
(2017).
24. Nakka, P., Raphael, B. J. & Ramachandran, S. Gene and network analysis of
common variants reveals novel associations in multiple complex diseases.
Genetics 204, 783–798 (2016).
25. Razick, S., Magklaras, G. & Donaldson, I. M. iRefIndex: a consolidated protein
interaction database with provenance. BMC Bioinform. 9, 405 (2008).
26. Cancer Genome Atlas Network. Comprehensive molecular portraits of human
breast tumours. Nature 490, 61–70 (2012).
27. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression proﬁles. Proc. Natl Acad.
Sci. USA 102, 15545–15550 (2005).
28. Joshi-Tope, G. et al. Reactome: a knowledgebase of biological pathways.
Nucleic Acids Res. 33, D428–D432 (2005).
29. Liberzon, A. et al. The Molecular Signatures Database Hallmark Gene Set
Collection. Cell Syst. 1, 417–425 (2015).
30. Lappano, R. & Maggiolini, M. G protein-coupled receptors: novel targets for
drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47–60 (2011).
31. Kisfalvi, K., Rey, O., Young, S. H., Sinnett-Smith, J. & Rozengurt, E. Insulin
potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate
hydrolysis induced by Gq protein-coupled receptor agonists through an
mTOR-dependent pathway. Endocrinology 148, 3246–3257 (2007).
32. Sassmann, A. et al. The Gq/G11-mediated signaling pathway is critical for
autocrine potentiation of insulin secretion in mice. J. Clin. Invest. 120,
2184–2193 (2010).
33. Imamura, T. et al. G alpha-q/11 protein plays a key role in insulin-induced
glucose transport in 3T3-L1 adipocytes. Mol. Cell. Biol. 19, 6765–6774 (1999).
34. Nierodzik, M. L. & Karpatkin, S. Thrombin induces tumor growth, metastasis,
and angiogenesis: evidence for a thrombin-regulated dormant tumor
phenotype. Cancer Cell 10, 355–362 (2006).
35. Woulfe, D. S. Platelet G protein-coupled receptors in hemostasis and
thrombosis. J. Thromb. Haemost. 3, 2193–2200 (2005).
36. Lal, I., Dittus, K. & Holmes, C. E. Platelets, coagulation and ﬁbrinolysis in
breast cancer progression. Breast Cancer Res. 15, 207 (2013).
37. Gaucher, J., Montellier, E. & Sassone-Corsi, P. Molecular cogs: interplay
between circadian clock and cell cycle. Trends Cell Biol. 28, 368–379 (2018).
38. Hansen, J. & Stevens, R. G. Case-control study of shift-work and breast cancer
risk in Danish nurses: impact of shift systems. Eur. J. Cancer 48, 1722–1729
(2012).
39. Knutsson, A. et al. Breast cancer among shift workers: results of the WOLF
longitudinal cohort study. Scand. J. Work. Environ. Health 39, 170–177
(2013).
40. Travis, R. C. et al. Night shift work and breast cancer incidence: three
prospective studies and meta-analysis of published studies. J. Natl Cancer Inst.
108, djw169 (2016).
41. Rabstein, S. et al. Night work and breast cancer estrogen receptor status-
results from the German GENICA study. Scand. J. Work. Environ. Health 39,
448–455 (2013).
42. Zienolddiny, S. et al. Analysis of polymorphisms in the circadian-related genes
and breast cancer risk in Norwegian nurses working night shifts. Breast
Cancer Res. 15, R53 (2013).
43. Reszka, E., Przybek, M., Muurlink, O. & Pepłonska, B. Circadian gene variants
and breast cancer. Cancer Lett. 390, 137–145 (2017).
44. Cadenas, C. et al. Loss of circadian clock gene expression is associated with
tumor progression in breast cancer. Cell Cycle 13, 3282–3291 (2014).
45. Ha, N.-H., Long, J., Cai, Q., Shu, X. O. & Hunter, K. W. The circadian rhythm
gene Arntl2 is a metastasis susceptibility gene for estrogen receptor-negative
breast cancer. PLoS Genet. 12, e1006267 (2016).
46. Yang, X. et al. The circadian clock gene per1 suppresses cancer cell
proliferation and tumor growth at speciﬁc times of day. Chronobiol. Int. 26,
1323–1339 (2009).
47. Komatsu, N. et al. The circadian gene Per1 plays an important role in cell
growth and DNA damage control in human cancer cells. Mol. Cell 22,
375–382 (2006).
48. Kuo, S.-J. et al. Deregulated expression of the PER1, PER2 and PER3 genes in
breast cancers. Carcinogenesis 26, 1241–1246 (2005).
49. Unsal-Kacmaz, K., Mullen, T. E., Kaufmann, W. K. & Sancar, A. Coupling of
human circadian and cell cycles by the timeless protein. Mol. Cell. Biol. 25,
3109–3116 (2005).
50. Rigaill, G. et al. TIPIN depletion leads to apoptosis in breast cancer cells. Mol.
Oncol. 9, 1580–1598 (2015).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14100-6 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:312 | https://doi.org/10.1038/s41467-019-14100-6 | www.nature.com/naturecommunications 9
51. Ashcroft, M. et al. Human CHCHD4 mitochondrial proteins regulate cellular
oxygen consumption rate and metabolism and provide a critical role in
hypoxia signaling and tumor progression. J. Clin. Invest. 122, 600–611 (2012).
52. Zhuang, J. et al. Mitochondrial disulﬁde relay mediates translocation of p53
and partitions its subcellular activity. Proc. Natl Acad. Sci. 110, 17356–17361
(2013).
53. Sun, Y. et al. Haploinsufﬁciency in the mitochondrial protein CHCHD4
reduces brain injury in a mouse model of neonatal hypoxia-ischemia. Cell
Death Dis. 8, e2781 (2017).
54. Windham, P. F. & Tinsley, H. N. CGMP signaling as a target for the
prevention and treatment of breast cancer. Semin. Cancer Biol. 31, 106–110
(2015).
55. Saravani, R., Karami-Tehrani, F., Hashemi, M., Aghaei, M. & Edalat, R.
Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis
in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif. 45,
199–206 (2012).
56. Aznar, S. & Lacal, J. C. Rho signals to cell growth and apoptosis. Cancer Lett.
165, 1–10 (2001).
57. Jilg, C. A. et al. PRK1/PKN1 controls migration and metastasis of androgen-
independent prostate cancer cells. Oncotarget 5, 12646–12664 (2014).
58. James, R. G. et al. Protein kinase PKN1 represses Wnt/β-catenin signaling in
human melanoma cells. J. Biol. Chem. 288, 34658–34670 (2013).
59. Dillon, L. & Miller, T. Therapeutic targeting of cancers with loss of PTEN
function. Curr. Drug Targets 15, 65–79 (2014).
60. Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumor-suppressive
metabolic state. Cell 149, 49–62 (2012).
61. Chen, L. & Guo, D. The functions of tumor suppressor PTEN in innate and
adaptive immunity. Cell. Mol. Immunol. 14, 581–589 (2017).
62. Neo, S. H. et al. Use of a novel cytotoxic HEXIM1 peptide in the directed
breast cancer therapy. Oncotarget 7, 5483–5494 (2016).
63. Hartman, M. et al. Is breast cancer prognosis inherited? Breast Cancer Res. 9,
R39 (2007).
64. Möller, S. et al. The heritability of breast cancer among women in the nordic
twin study of cancer. Cancer Epidemiol. Biomark. Prev. 25, 145–150 (2016).
65. Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M. & Sherman, M. E.
How many etiological subtypes of breast cancer: two, three, four, or more? J.
Natl Cancer Inst. 106, 1–11 (2014).
66. Kao, P. Y. P., Leung, K. H., Chan, L. W. C., Yip, S. P. & Yap, M. K. H. Pathway
analysis of complex diseases for GWAS, extending to consider rare variants,
multi-omics and interactions. Biochim. Biophys. Acta 1861, 335–353 (2017).
67. Reyna, M. A., Leiserson, M. D. M. & Raphael, B. J. Hierarchical HotNet:
identifying hierarchies of altered subnetworks. Bioinformatics 34, i972–i980
(2018).
68. Michailidou, K. et al. Large-scale genotyping identiﬁes 41 new loci associated
with breast cancer risk. Nat. Genet. 45, 353–361 (2013). 361e1-2.
69. 1000 Genomes Project Consortium et al. A map of human genome variation
from population-scale sequencing. Nature 467, 1061–1073 (2010).
70. Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method
for thousands of genomes. Nat. Methods 9, 179–181 (2011).
71. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands
of genomes. G3 (Bethesda) 1, 457–470 (2011).
72. Vandin, F., Clay, P., Upfal, E. & Raphael, B. J. Discovery of mutated
subnetworks associated with clinical data in cancer. Pac. Symp. Biocomput.
55–66 (2012).
73. Vandin, F., Upfal, E. & Raphael, B. J. Algorithms for detecting signiﬁcantly
mutated pathways in cancer. J. Comput. Biol. 18, 507–522 (2011).
74. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized
linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).
75. Shannon, P. et al. Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
76. Calderone, A., Castagnoli, L. & Cesareni, G. mentha: a resource for browsing
integrated protein-interaction networks. Nat. Methods 10, 690–691 (2013).
77. Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks. Bioinformatics 25,
1091–1093 (2009).
78. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map:
a network-based method for gene-set enrichment visualization and
interpretation. PLoS ONE 5, e13984 (2010).
Acknowledgements
BCAC: We thank all the individuals who took part in these studies and all the
researchers, clinicians, technicians, and administrative staff who have enabled this work
to be carried out. We acknowledge all contributors to the COGS and OncoArray study
design, chip design, genotyping, and genotype analyses. ABCFS: Maggie Angelakos, Judi
Maskiell, Gillian Dite. ABCS: Frans Hogervorst, Sten Cornelissen and Annegien Broeks.
ABCTB Investigators: Rosemary Balleine, Robert Baxter, Stephen Braye, Jane Carpenter,
Jane Dahlstrom, John Forbes, Soon Lee, Debbie Marsh, Adrienne Morey, Nirmala
Pathmanathan, Rodney Scott, Allan Spigelman, Nicholas Wilcken, Desmond Yip. BBCS:
Eileen Williams, Elaine Ryder-Mills, Kara Sargus. BCINIS: Dr. K. Landsman, Dr. N.
Gronich, Dr. A. Flugelman, Dr. W. Saliba, Dr. E. Liani, Dr. I. Cohen, Dr. S. Kalet,
Dr. V. Friedman, Dr. O. Barnet. BIGGS: Niall McInerney, Gabrielle Colleran, Andrew
Rowan, Angela Jones. BREOGAN: Manuela Gago-Dominguez, Jose Esteban Castelao,
Angel Carracedo, Victor Muñoz Garzón, Alejandro Novo Domínguez, Maria Elena
Martinez, Sara Miranda Ponte, Carmen Redondo Marey, Maite Peña Fernández, Manuel
Enguix Castelo, Maria Torres, Manuel Calaza, José Antúnez, Máximo Fraga; Joaquín
González-Carreró and the Department of Pathology and Biobank of University Hospital
Complex of Vigo, Instituto de Investigacion Biomedica Galicia Sur, SERGAS. BSUCH:
Peter Bugert, Medical Faculty Mannheim. CCGP: Styliani Apostolaki, Anna Margiolaki,
Georgios Nintos, Maria Perraki, Georgia Saloustrou, Georgia Sevastaki, Konstantinos
Pompodakis. CGPS: Dorthe Uldall Andersen, Maria Birna Arnadottir, Anne Bank,
Dorthe Kjeldgård Hansen, and the Danish Cancer Biobank. CNIO-BCS: Guillermo Pita,
Charo Alonso, Nuria Álvarez, Pilar Zamora, and Primitiva Menendez. CPS-II: Centers
for Disease Control and Prevention National Program of Cancer Registries. The National
Cancer Institute Surveillance Epidemiology, and End Results program. CTS: Leslie
Bernstein, Susan Neuhausen, James Lacey, Sophia Wang, Huiyan Ma, and Jessica Clague
DeHart. Dennis Deapen, Rich Pinder, and Eunjung Lee, Pam Horn-Ross, Peggy Rey-
nolds, Christina Clarke Dur and David Nelson, Hoda Anton-Culver, Argyrios Ziogas,
and Hannah Park and Fred Schumacher. DIETCOMPLYF: charity Against Breast Cancer
(Registered Charity Number 1121258) and the NCRN. Participants and the investigators
of EPIC (European Prospective Investigation into Cancer and Nutrition). ESTHER:
Hartwig Ziegler, Sonja Wolf, Volker Hermann, Christa Stegmaier, Katja Butterbach.
FHRISK: NIHR for funding. GC-HBOC: Stefanie Engert, Heide Hellebrand, Sandra
Kröber and LIFE. Markus Loefﬂer, Joachim Thiery, Matthias Nüchter, Ronny Baber.
GENICA: Dr. Margarete Fischer-Bosch [HB, Wing-Yee Lo], German Cancer Consortium
(DKTK), and German Cancer Research Center (DKFZ) [HB], gefördert durch die
Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes
und der Länder - EXC 2180 - 390900677 [HB], Evangelische Kliniken Bonn gGmbH,
Johanniter Krankenhaus, [Yon-Dschun Ko, Christian Baisch], University of Bonn,
Germany [Hans-Peter Fischer], Deutsches Krebsforschungszentrum (DKFZ), Heidel-
berg, Germany [UH], Institute for Prevention and Occupational Medicine of the German
Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum,
Germany [Thomas Brüning, Beate Pesch, Sylvia Rabstein, Anne Lotz]; University
Medical Center Hamburg-Eppendorf, Germany [Volker Harth]. HABCS: Michael Bre-
mer. HEBCS: Rainer Fagerholm, Kirsimari Aaltonen, Karl von Smitten, Irja Erkkilä.
HUBCS: Shamil Gantsev. KARMA and SASBAC: Swedish Medical Research Counsel.
KBCP: Eija Myöhänen, Helena Kemiläinen. kConFab/AOCS: Eveline Niedermayr,
Family Cancer Clinics and the Clinical Follow Up Study (received funding from the
NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National
Institute of Health (USA)). LMBC: Gilian Peuteman, Thomas Van Brussel, Evy-
Vanderheyden and Kathleen Corthouts. MARIE: Petra Seibold, Judith Heinz, Nadia Obi,
Sabine Behrens, Ursula Eilber, Muhabbet Celik and Til Olchers. MBCSG: Paolo Radice,
Jacopo Azzollini, Bernardo Bonanni, Bernard Peissel, Roberto Villa, Giulia Cagnoli, Irene
Feroce, and Cogentech Cancer Genetic Test Laboratory. NBCS: Kristine K. Sahlberg
(PhD), Lars Ottestad (MD), Rolf Kåresen (Prof. Em.) Dr. Ellen Schlichting (MD), Marit
Muri Holmen (MD), Toril Sauer (MD), Vilde Haakensen (MD), Olav Engebråten (MD),
Bjørn Naume (MD), Alexander Fosså (MD), Cecile E. Kiserud (MD), Kristin V. Rein-
ertsen (MD), Åslaug Helland (MD), Margit Riis (MD), Jürgen Geisler (MD) and
OSBREAC. NHS/NHS2: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA,
ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA,
WA, WY. OBCS: Arja Jukkola-Vuorinen, Mervi Grip, Saila Kauppila, Meeri Otsukka,
Leena Keskitalo and Kari Mononen. OFBCR: Teresa Selander, Nayana Weerasooriya.
ORIGO: E. Krol-Warmerdam, and J. Blom. PBCS: Louise Brinton, Mark Sherman,
Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao, Michael
Stagner. The ethical approval for the POSH study is MREC /00/6/69, UKCRN ID: 1137.
Experimental Cancer Medicine Centre (ECMC) supported Faculty of Medicine Tissue
Bank and the Faculty of Medicine DNA Banking resource. PREFACE: Sonja Oeser and
Silke Landrith. PROCAS: NIHR for funding. RBCS: Petra Bos, Jannet Blom, Ellen Crepin,
Elisabeth Huijskens, Anja Kromwijk-Nieuwlaat, Annette Heemskerk, the Erasmus MC
Family Cancer Clinic. SBCS: Sue Higham, Helen Cramp, Dan Connley, Ian Brock,
Sabapathy Balasubramanian and Malcolm W.R. Reed. We thank the SEARCH and EPIC
teams. SKKDKFZS: SUCCESS Study teams in Munich, Duessldorf, Erlangen and Ulm.
SZBCS: Ewa Putresza. UCIBCS: Irene Masunaka. UKBGS: Breast Cancer Now and the
Institute of Cancer Research and NHS funding to the Royal Marsden/ICR NIHR Bio-
medical Research Centre. WHI: investigators and staff for their dedication. BCAC is
funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's
Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784
for BRIDGES and B-CAST respectively), and by the European Community´s Seventh
Framework Programme under grant agreement number 223175 (grant number
HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 Research and Innovation
Programme funding source had no role in study design, data collection, data analysis,
data interpretation or writing of the report. Genotyping of the OncoArray was funded by
the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PER-
SPECTIVE project supported by the Government of Canada through Genome Canada
and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère
de l’Économie, Science et Innovation du Québec through Genome Québec and the
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14100-6
10 NATURE COMMUNICATIONS |          (2020) 11:312 | https://doi.org/10.1038/s41467-019-14100-6 | www.nature.com/naturecommunications
PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for the iCOGS
infrastructure came from: the European Community's Seventh Framework Programme
under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer
Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/
A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of
Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19
CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence
(W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the
CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the
Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE
Consortium was funded by U19 CA148065. ABCFS was supported by grant UM1
CA164920 from the National Cancer Institute (USA). The content of this manuscript
does not necessarily reﬂect the views or policies of the National Cancer Institute or any of
the collaborating centers in the in the Breast Cancer Family Registry (BCFR), nor does
mention of trade names, commercial products, or organizations imply endorsement by
the USA Government or the BCFR. The ABCFS was also supported by the National
Health and Medical Research Council of Australia, the New South Wales Cancer
Council, the Victorian Health Promotion Foundation (Australia) and the Victorian
Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research
Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior
Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants
NKI 2007-3839; 2009-4363; 2015-7632]. The ABCTB was supported by the National
Health and Medical Research Council of Australia, The Cancer Institute NSW and the
National Breast Cancer Foundation. The work of the BBCC was partly funded by ELAN-
Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research
UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical
Research Centre, and the National Cancer Research Network (NCRN). For the BCFR-
NY, BCFR-PA, BCFR-UT this work was supported by grant UM1 CA164920 from the
National Cancer Institute. For BIGGS, ES is supported by NIHR Comprehensive Bio-
medical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership
with King's College London, United Kingdom. IT is supported by the Oxford Biomedical
Research Centre. The BREOGAN is funded by Acción Estratégica de Salud del Instituto
de Salud Carlos III FIS PI12/02125/Coﬁnanciado FEDER; Acción Estratégica de Salud del
Instituto de Salud Carlos III FIS PI17/00918/Coﬁnanciado FEDER; Acción Estratégica de
Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos
Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur.
Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain;
Grant 10CSA012E, Consellería de Industria Programa Sectorial de Investigación Apli-
cada, PEME I + D e I + D Suma del Plan Gallego de Investigación, Desarrollo e
Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain;
Grant EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de
Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Minis-
terio de Economia y Competitividad, Xunta de Galicia, Spain. The BSUCH study was
supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German
Cancer Research Center (DKFZ). CCGP is supported by funding from the University of
Crete. The CECILE study was supported by Fondation de France, Institut National du
Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire,
de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la
Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and
Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte
Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red
Temática de Investigación Cooperativa en Cáncer and grants from the Asociación
Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/00923 and
PI12/00070). The American Cancer Society funds the creation, maintenance, and
updating of the CPS-II cohort. The CTS was initially supported by the California Breast
Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500)
and is currently funded through the National Institutes of Health (R01 CA77398, UM1
CA164917, and U01 CA199277). Collection of cancer incidence data was supported by
the California Department of Public Health as part of the statewide cancer reporting
program mandated by California Health and Safety Code Section 103885. The University
of Westminster curates the DietCompLyf database funded by Against Breast Cancer
Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is ﬁnancially
supported by the European Commission (DG-SANCO) and the International Agency for
Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer,
Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National
de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid,
German Cancer Research Center (DKFZ), Federal Ministry of Education and Research
(BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation
(Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National
Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS),
Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds,
Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF),
Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to
Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias,
Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer
Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-
Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-
Oxford) (United Kingdom). The ESTHER study was supported by a grant from the
Baden Württemberg Ministry of Science, Research and Arts. Additional cases were
recruited in the context of the VERDI study, which was supported by a grant from the
German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR
0707-10031. Prof D Gareth Evans is supported by the NIHR Manchester Biomedical
Research Centre (IS-BRC-1215-20007). The GC-HBOC is supported by the German
Cancer Aid (grant no 110837, coordinator: Rita K. Schmutzler, Cologne). This work was
also funded by the European Regional Development Fund and Free State of Saxony,
Germany (LIFE - Leipzig Research Centre for Civilization Diseases, project numbers 713-
241202, 713-241202, 14505/2470, 14575/2470). The GENICA was funded by the Federal
Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/
8, 01KW9977/0, and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches
Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occu-
pational Medicine of the German Social Accident Insurance, Institute of the Ruhr
University Bochum (IPA), Bochum, as well as the Department of Internal Medicine,
Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The
GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer
Research Center (DKFZ). The HABCS study was supported by the Claudia von Schilling
Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, and by
the Rudolf Bartling Foundation. The HEBCS was ﬁnancially supported by the Helsinki
University Central Hospital Research Fund, Academy of Finland (266528), the Finnish
Cancer Society, and the Sigrid Juselius Foundation. The HUBCS was supported by a
grant from the German Federal Ministry of Research and Education (RUS08/017), and
by the Russian Foundation for Basic Research and the Federal Agency for Scientiﬁc
Organizations for support the Bioresource collections and RFBR grants 14-04-97088, 17-
29-06014 and 17-44-020498. Financial support for KARBAC was provided through the
regional agreement on medical training and clinical research (ALF) between Stockholm
County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V
Jubilee foundation and Bert von Kantzows foundation. The KARMA study was sup-
ported by Märit and Hans Rausings Initiative Against Breast Cancer. The KBCP was
ﬁnancially supported by the special Government Funding (EVO) of Kuopio University
Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by
the strategic funding of the University of Eastern Finland. kConFab is supported by a
grant from the National Breast Cancer Foundation, and previously by the National
Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the
Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the
Cancer Foundation of Western Australia. LMBC is supported by the “Stichting tegen
Kanker.” The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR
I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German
Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research
(BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Asso-
ciation for Cancer Research (AIRC) and by funds from the Italian citizens who allocated
the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto
Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects
“5x1000”). The MCBCS was supported by the NIH grants CA192393, CA116167,
CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast
Cancer [CA116201], and the Breast Cancer Research Foundation and a generous.pngt
from the David F. and Margaret T. Grohne Family Foundation. MCCS cohort recruit-
ment was funded by VicHealth and Cancer Council Victoria. The MCCS was further
supported by Australian NHMRC grants 209057 and 396414, and by infrastructure
provided by Cancer Council Victoria. Cases and their vital status were ascertained
through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and
Welfare (AIHW), including the National Death Index and the Australian Cancer
Database. The MEC was supported by NIH grants CA63464, CA54281, CA098758,
CA132839 and CA164973. The MISS study is supported by funding from ERC-2011-
294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local
hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was
supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150.
The NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer Research;
the Research Council of Norway grant 193387/V50 (to A-L Børresen-Dale and V.N.
Kristensen) and grant 193387/H10 (to A-L Børresen-Dale and V.N. Kristensen), South
Eastern Norway Health Authority (grant 39346 to A-L Børresen-Dale) and the Nor-
wegian Cancer Society (to A-L Børresen-Dale and V.N. Kristensen). The NC-BCFR and
OFBCR were supported by grant UM1 CA164920 from the National Cancer Institute
(USA). The NCBCS was funded by Komen Foundation, the National Cancer Institute
(P50 CA058223, U54 CA156733, U01 CA179715), and the North Carolina University
Cancer Research Fund. The NHS was supported by NIH grants P01 CA87969, UM1
CA186107, and U19 CA148065. The NHS2 was supported by NIH grants UM1
CA176726 and U19 CA148065. The OBCS was supported by research grants from the
Finnish Cancer Foundation, the Academy of Finland (grant number 250083, 122715 and
Center of Excellence grant number 251314), the Finnish Cancer Foundation, the Sigrid
Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation
and the special Governmental EVO funds for Oulu University Hospital-based research
activities. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-
1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-
NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer
Institute, Department of Health and Human Services, USA. Genotyping for PLCO was
supported by the Intramural Research Program of the National Institutes of Health, NCI,
Division of Cancer Epidemiology and Genetics. The PLCO is supported by the
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14100-6 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:312 | https://doi.org/10.1038/s41467-019-14100-6 | www.nature.com/naturecommunications 11
Intramural Research Program of the Division of Cancer Epidemiology and Genetics and
supported by contracts from the Division of Cancer Prevention, National Cancer
Institute, National Institutes of Health. The POSH study is funded by Cancer Research
UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast
Cancer Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR
0707-10031. PROCAS is funded from NIHR grant PGfAR 0707-10031. The RBCS was
funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The
SASBAC study was supported by funding from the Agency for Science, Technology and
Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the
Susan G. Komen Breast Cancer Foundation. The SBCS was supported by Shefﬁeld
Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. SEARCH is
funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK
National Institute for Health Research Biomedical Research Centre at the University of
Cambridge. The University of Cambridge has received salary support for PDPP from the
NHS in the East of England through the Clinical Academic Reserve. SKKDKFZS is
supported by the DKFZ. The SMC is funded by the Swedish Cancer Foundation and the
Swedish Research Council (SIMPLER, VR 2017-00644). The SZBCS was supported by
Grant PBZ_KBN_122/P05/2004. The UCIBCS component of this research was sup-
ported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420].
The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR),
London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The
USRT Study was funded by Intramural Research Funds of the National Cancer Institute,
Department of Health and Human Services, USA. The WHI program is funded by the
National Heart, Lung, and Blood Institute, the US National Institutes of Health and the
US Department of Health and Human Services (HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, and HHSN271201100004C). This work was also funded by NCI
U19 CA148065-01.
Author contributions
M.K.S. and S.C. conceived the study. M.E.G. performed the data analyses. M.K.S., S.C.
and M.E.G. were involved in the interpretation of the data. S.C. provided statistical and
computational support for the data analyses. R.K., Q.W., M.K.B. and J.D. provided
database support. M.E.G., M.K.S. and S.C. wrote the manuscript. All authors contributed
data from their own studies, helped revise the manuscript, and approved the ﬁnal ver-
sion. All authors consented to this publication.
Competing interests
A.Ashworth is a cofounder of Tango Therapeutics, Azkarra Therapeutics, and Ovibio, is
an advisor for Gladiator, Prolynx, Bluestar, Earli and Genentech, reports receiving
commercial research grants from AstraZeneca and SPARC, and has ownership interest in
patents on the use of PARP inhibitors, held jointly with AstraZeneca. The remaining
authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
019-14100-6.
Correspondence and requests for materials should be addressed to S.C. or M.K.S.
Peer review information: Nature Communications thanks Walter Kolch, Kerstin Meyer,
and the other anonymous reviewer(s) for their contribution to the peer review of this
work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
Maria Escala-Garcia1, Jean Abraham2,3,4, Irene L. Andrulis 5,6, Hoda Anton-Culver7, Volker Arndt 8,
Alan Ashworth9, Paul L. Auer10,11, Päivi Auvinen12,13,14, Matthias W. Beckmann15, Jonathan Beesley16,
Sabine Behrens17, Javier Benitez18,19, Marina Bermisheva20, Carl Blomqvist21,22, William Blot23,24,
Natalia V. Bogdanova25,26,27, Stig E. Bojesen 28,29,30, Manjeet K. Bolla31, Anne-Lise Børresen-Dale32,33,
Hiltrud Brauch 34,35,36, Hermann Brenner8,36,37, Sara Y. Brucker38, Barbara Burwinkel39,40,
Carlos Caldas 41,42, Federico Canzian 43, Jenny Chang-Claude17,44, Stephen J. Chanock 45,
Suet-Feung Chin 46, Christine L. Clarke47, Fergus J. Couch48, Angela Cox49, Simon S. Cross50, Kamila Czene51,
Mary B. Daly52, Joe Dennis 31, Peter Devilee 53,54, Janet A. Dunn55, Alison M. Dunning 2,
Miriam Dwek 56, Helena M. Earl4,57, Diana M. Eccles58, A. Heather Eliassen59,60, Carolina Ellberg 61,
D. Gareth Evans62,63,64, Peter A. Fasching 15,65, Jonine Figueroa45,66,67, Henrik Flyger68,
Manuela Gago-Dominguez69,70, Susan M. Gapstur71, Montserrat García-Closas 45,72,
José A. García-Sáenz 73, Mia M. Gaudet71, Angela George74, Graham G. Giles 75,76,77, David E. Goldgar78,
Anna González-Neira18, Mervi Grip79, Pascal Guénel 80, Qi Guo81, Christopher A. Haiman82,
Niclas Håkansson 83, Ute Hamann84, Patricia A. Harrington2, Louise Hiller55, Maartje J. Hooning85,
John L. Hopper76, Anthony Howell86, Chiun-Sheng Huang87, Guanmengqian Huang84, David J. Hunter60,88,89,
Anna Jakubowska90,91, Esther M. John92, Rudolf Kaaks17, Pooja Middha Kapoor 17,93, Renske Keeman 1,
Cari M. Kitahara94, Linetta B. Koppert95, Peter Kraft 60,88, Vessela N. Kristensen32,33,
Diether Lambrechts 96,97, Loic Le Marchand98, Flavio Lejbkowicz99, Annika Lindblom100,101, Jan Lubiński90,
Arto Mannermaa14,102,103, Mehdi Manoochehri84, Siranoush Manoukian104, Sara Margolin105,106,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14100-6
12 NATURE COMMUNICATIONS |          (2020) 11:312 | https://doi.org/10.1038/s41467-019-14100-6 | www.nature.com/naturecommunications
Maria Elena Martinez70,107, Tabea Maurer44, Dimitrios Mavroudis108, Alfons Meindl109,
Roger L. Milne 75,76,110, Anna Marie Mulligan111,112, Susan L. Neuhausen113, Heli Nevanlinna 114,
William G. Newman 62,63, Andrew F. Olshan115, Janet E. Olson 116, Håkan Olsson61, Nick Orr 117,
Paolo Peterlongo 118, Christos Petridis119, Ross L. Prentice10, Nadege Presneau56, Kevin Punie 120,
Dhanya Ramachandran 26, Gad Rennert 99, Atocha Romero 121, Mythily Sachchithananthan47,
Emmanouil Saloustros 122, Elinor J. Sawyer119, Rita K. Schmutzler123,124, Lukas Schwentner125,
Christopher Scott 116, Jacques Simard 126, Christof Sohn127, Melissa C. Southey110,128,
Anthony J. Swerdlow74,129, Rulla M. Tamimi59,60,88, William J. Tapper130, Manuel R. Teixeira 131,132,
Mary Beth Terry133, Heather Thorne134,135, Rob A.E.M. Tollenaar136, Ian Tomlinson 137,138,
Melissa A. Troester115, Thérèse Truong 80, Clare Turnbull74, Celine M. Vachon116, Lizet E. van der Kolk139,
Qin Wang31, Robert Winqvist 140,141, Alicja Wolk 83,142, Xiaohong R. Yang45, Argyrios Ziogas 7,
Paul D.P. Pharoah 2,31, Per Hall51,105, Lodewyk F.A. Wessels143,144, Georgia Chenevix-Trench16,
Gary D. Bader 6,145, Thilo Dörk 26, Douglas F. Easton 2,31, Sander Canisius 1,143,147* &
Marjanka K. Schmidt 1,146,147*
1Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
2Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK. 3Cambridge Experimental Cancer
Medicine Centre, Cambridge, UK. 4Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, University of Cambridge NHS
Foundation Hospitals, Cambridge, UK. 5Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai
Hospital, Toronto, ON, Canada. 6Department of Molecular Genetics, University of Toronto, Toronto, Canada. 7Department of Epidemiology, Genetic
Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA. 8Division of Clinical Epidemiology and Aging Research, German
Cancer Research Center (DKFZ), Heidelberg, Germany. 9UCSF Helen Diller Family Comprehensive Cancer Center, University of California San
Francisco, San Francisco, CA, USA. 10Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 11Zilber School of
Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA. 12Cancer Center, Kuopio University Hospital, Kuopio, Finland. 13Institute of
Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, Finland. 14Translational Cancer Research Area, University of Eastern Finland,
Kuopio, Finland. 15Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-
Alexander-University Erlangen-Nuremberg, Erlangen, Germany. 16Department of Genetics and Computational Biology, QIMR Berghofer Medical
Research Institute, Brisbane, QLD, Australia. 17Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
18Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. 19Biomedical Network on Rare Diseases
(CIBERER), Madrid, Spain. 20Institute of Biochemistry and Genetics, Ufa Scientiﬁc Center of Russian Academy of Sciences, Ufa, Russia.
21Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. 22Department of Oncology, Örebro University
Hospital, Örebro, Sweden. 23Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center,
Vanderbilt University School of Medicine, Nashville, TN, USA. 24International Epidemiology Institute, Rockville, MD, USA. 25Department of
Radiation Oncology, Hannover Medical School, Hannover, Germany. 26Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
27N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus. 28Copenhagen General Population Study, Herlev and
Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. 29Department of Clinical Biochemistry, Herlev and Gentofte Hospital,
Copenhagen University Hospital, Herlev, Denmark. 30Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
31Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK. 32Department
of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. 33Institute of Clinical Medicine, Faculty
of Medicine, University of Oslo, Oslo, Norway. 34Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany. 35iFIT-Cluster
of Excellence, University of Tuebingen, Tuebingen, Germany. 36German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK),
Heidelberg, Germany. 37Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT),
Heidelberg, Germany. 38Department of Gynecology and Obstetrics, University of Tübingen, Tübingen, Germany. 39Molecular Epidemiology Group,
C080, German Cancer Research Center (DKFZ), Heidelberg, Germany. 40Molecular Biology of Breast Cancer, University Womens Clinic
Heidelberg, University of Heidelberg, Heidelberg, Germany. 41Cancer Research UK Cambridge Institute, Department of Oncology, Li Ka Shing
Centre, University of Cambridge, Cambridge, UK. 42Breast Cancer Programme, CRUK Cambridge Cancer Centre and NIHR Biomedical Research
Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 43Genomic Epidemiology Group, German Cancer Research Center
(DKFZ), Heidelberg, Germany. 44Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-
Eppendorf, Hamburg, Germany. 45Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer
Institute, National Institutes of Health, Bethesda, MD, USA. 46Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
47Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia. 48Department of Laboratory Medicine and Pathology,
Mayo Clinic, Rochester, MN, USA. 49Department of Oncology and Metabolism, Shefﬁeld Institute for Nucleic Acids (SInFoNiA), University of
Shefﬁeld, Shefﬁeld, UK. 50Academic Unit of Pathology, Department of Neuroscience, University of Shefﬁeld, Shefﬁeld, UK. 51Department of Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 52Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia,
PA, USA. 53Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. 54Department of Human Genetics, Leiden
University Medical Center, Leiden, The Netherlands. 55Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. 56Department of
Biomedical Sciences, Faculty of Science and Technology, University of Westminster, London, UK. 57Department of Oncology, University of
Cambridge, Cambridge, UK. 58Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK. 59Channing
Division of Network Medicine, Department of Medicine, Brigham andWomen’s Hospital, Harvard Medical School, Boston, MA, USA. 60Department
of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 61Department of Cancer Epidemiology, Clinical Sciences, Lund
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14100-6 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:312 | https://doi.org/10.1038/s41467-019-14100-6 | www.nature.com/naturecommunications 13
University, Lund, Sweden. 62Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health,
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. 63Genomic Medicine, St Mary’s Hospital, Manchester
Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre,
Manchester, UK. 64NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University NHS
Foundation Trust, Manchester, UK. 65Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University
of California at Los Angeles, Los Angeles, CA, USA. 66Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh
Medical School, Edinburgh, UK. 67Cancer Research UK Edinburgh Centre, Edinburgh, UK. 68Department of Breast Surgery, Herlev and Gentofte
Hospital, Copenhagen University Hospital, Herlev, Denmark. 69Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de
Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de
Compostela, Spain. 70Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. 71Epidemiology Research Program, American
Cancer Society, Atlanta, GA, USA. 72Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. 73Medical Oncology
Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer
(CIBERONC), Madrid, Spain. 74Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. 75Cancer Epidemiology
Division, Cancer Council Victoria, Melbourne, VIC, Australia. 76Centre for Epidemiology and Biostatistics, Melbourne School of Population and
Global Health, The University of Melbourne, Melbourne, VIC, Australia. 77Department of Epidemiology and Preventive Medicine, Monash
University, Melbourne, VIC, Australia. 78Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake
City, UT, USA. 79Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland. 80Cancer & Environment Group, Center for
Research in Epidemiology and Population Health (CESP), University Paris-Saclay, INSERM, University Paris-Sud, Villejuif, France. 81Cardiovascular
Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 82Department of Preventive Medicine,
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 83Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden. 84Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. 85Department of
Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 86Division of Cancer Sciences, University of
Manchester, Manchester, UK. 87Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine,
Taipei, Taiwan. 88Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
89Nufﬁeld Department of Population Health, University of Oxford, Oxford, UK. 90Department of Genetics and Pathology, Pomeranian Medical
University, Szczecin, Poland. 91Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University,
Szczecin, Poland. 92Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA,
USA. 93Faculty of Medicine, University of Heidelberg, Heidelberg, Germany. 94Radiation Epidemiology Branch, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, Bethesda, MD, USA. 95Department of Surgical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute,
Rotterdam, The Netherlands. 96VIB, VIB Center for Cancer Biology, Leuven, Belgium. 97Laboratory for Translational Genetics, Department of Human
Genetics, University of Leuven, Leuven, Belgium. 98Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA. 99Carmel
Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel. 100Department of Molecular Medicine and
Surgery, Karolinska Institutet, Stockholm, Sweden. 101Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
102Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland. 103Department of Clinical
Pathology, Imaging Center, Kuopio University Hospital, Kuopio, Finland. 104Unit of Medical Genetics, Department of Medical Oncology and
Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT), Milan, Italy. 105Department of Oncology, Sšdersjukhuset,
Stockholm, Sweden. 106Department of Clinical Science and Education, Sšdersjukhuset, Karolinska Institutet, Stockholm, Sweden. 107Department of
Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. 108Department of Medical Oncology, University Hospital
of Heraklion, Heraklion, Greece. 109Department of Gynecology and Obstetrics, Ludwig Maximilian University of Munich, Munich, Germany.
110Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia. 111Department of Laboratory
Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 112Laboratory Medicine Program, University Health Network, Toronto, ON,
Canada. 113Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. 114Department of Obstetrics and
Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. 115Department of Epidemiology, Lineberger Comprehensive Cancer
Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 116Department of Health Sciences Research, Mayo Clinic, Rochester, MN,
USA. 117Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Ireland, UK. 118Genome Diagnostics Program, IFOM - the
FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy. 119Research Oncology, Guy’s Hospital, King’s College
London, London, UK. 120Department of Oncology, Leuven Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven,
Leuven, Belgium. 121Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. 122Department of Oncology, University
Hospital of Larissa, Larissa, Greece. 123Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany.
124Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. 125Department of Gynaecology and Obstetrics,
University Hospital Ulm, Ulm, Germany. 126Genomics Center, Research Center, Centre Hospitalier Universitaire de Québec - Université Laval,
Québec City, QC, Canada. 127National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany. 128Department of Clinical
Pathology, The University of Melbourne, Melbourne, VIC, Australia. 129Division of Breast Cancer Research, The Institute of Cancer Research,
London, UK. 130Faculty of Medicine, University of Southampton, Southampton, UK. 131Department of Genetics, Portuguese Oncology Institute,
Porto, Portugal. 132Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal. 133Department of Epidemiology, Mailman School of
Public Health, Columbia University, New York, NY, USA. 134Peter MacCallum Cancer Center, Melbourne, VIC, Australia. 135Sir Peter MacCallum
Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. 136Department of Surgery, Leiden University Medical Center,
Leiden, The Netherlands. 137Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. 138Wellcome Trust Centre for
Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK. 139Family Cancer Clinic, The Netherlands Cancer
Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 140Biocenter Oulu, Cancer and Translational Medicine Research Unit,
Laboratory of Cancer Genetics and Tumor Biology, University of Oulu, Oulu, Finland. 141Laboratory of Cancer Genetics and Tumor Biology, Northern
Finland Laboratory Centre Oulu, Oulu, Finland. 142Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. 143Division of Molecular
Carcinogenesis, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 144Faculty of EEMCS, Delft
University of Technology, Delft, The Netherlands. 145The Donnelly Centre, University of Toronto, Toronto, ON, Canada. 146Division of Psychosocial
Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 147These authors
jointly supervised this work: Sander Canisius, Marjanka K. Schmidt. *email: s.canisius@nki.nl; mk.schmidt@nki.nl
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14100-6
14 NATURE COMMUNICATIONS |          (2020) 11:312 | https://doi.org/10.1038/s41467-019-14100-6 | www.nature.com/naturecommunications
